147 related articles for article (PubMed ID: 11726032)
1. Cytokine-based immunotherapy of allergic disease.
Lewkowich IP; HayGlass KT
Arch Immunol Ther Exp (Warsz); 2001; 49(4):293-302. PubMed ID: 11726032
[TBL] [Abstract][Full Text] [Related]
2. Endogenous IFN-gamma and IL-18 production directly limit induction of type 2 immunity in vivo.
Lewkowich IP; HayGlass KT
Eur J Immunol; 2002 Dec; 32(12):3536-45. PubMed ID: 12442336
[TBL] [Abstract][Full Text] [Related]
3. Recombinant interleukin-12 and interleukin-18 antitumor therapy in a guinea-pig hepatoma cell implant model.
Shiratori I; Suzuki Y; Oshiumi H; Begum NA; Ebihara T; Matsumoto M; Hazeki K; Kodama K; Kashiwazaki Y; Seya T
Cancer Sci; 2007 Dec; 98(12):1936-42. PubMed ID: 17888032
[TBL] [Abstract][Full Text] [Related]
4. Importance of the inducible costimulator molecule for the induction of allergic immune responses and its decreased expression on T helper cells after venom immunotherapy.
Bellinghausen I; Klostermann B; Böttcher I; Knop J; Saloga J
Immunology; 2004 May; 112(1):80-6. PubMed ID: 15096187
[TBL] [Abstract][Full Text] [Related]
5. Intranasal IL-12 produces discreet pulmonary and systemic effects on allergic inflammation and airway reactivity.
Matsuse H; Kong X; Hu J; Wolf SF; Lockey RF; Mohapatra SS
Int Immunopharmacol; 2003 Apr; 3(4):457-68. PubMed ID: 12689651
[TBL] [Abstract][Full Text] [Related]
6. Allergen rush immunotherapy increases interleukin (IL)-12 production and IL-12 receptor beta2 chain expression in patients with allergic asthma.
Tazaki T; Minoguchi K; Yokoe T; Oda N; Hashimoto T; Tanaka A; Okada S; Yamamoto Y; Watanabe Y; Adachi M
Cell Immunol; 2004 Mar; 228(1):20-6. PubMed ID: 15203316
[TBL] [Abstract][Full Text] [Related]
7. Engineered recombinant ovomucoid third domain can modulate allergenic response in Balb/c mice model.
Rupa P; Mine Y
Biochem Biophys Res Commun; 2006 Apr; 342(3):710-7. PubMed ID: 16494843
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-13 in asthma pathogenesis.
Wills-Karp M
Immunol Rev; 2004 Dec; 202():175-90. PubMed ID: 15546393
[TBL] [Abstract][Full Text] [Related]
9. Allergen-specific T lymphocytes as targets for specific immunotherapy: striking at the roots of type I allergy.
Bohle B
Arch Immunol Ther Exp (Warsz); 2002; 50(4):233-41. PubMed ID: 12371619
[TBL] [Abstract][Full Text] [Related]
10. Sustained T-bet expression confers polarized human TH2 cells with TH1-like cytokine production and migratory capacities.
Lametschwandtner G; Biedermann T; Schwärzler C; Günther C; Kund J; Fassl S; Hinteregger S; Carballido-Perrig N; Szabo SJ; Glimcher LH; Carballido JM
J Allergy Clin Immunol; 2004 May; 113(5):987-94. PubMed ID: 15131585
[TBL] [Abstract][Full Text] [Related]
11. [Regulation of Th1 and Th2 immune responses by IL-18].
Nakanishi K
Kekkaku; 2002 Feb; 77(2):87-93. PubMed ID: 11905033
[TBL] [Abstract][Full Text] [Related]
12. Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers.
Gardner LM; Thien FC; Douglass JA; Rolland JM; O'Hehir RE
Clin Exp Allergy; 2004 Aug; 34(8):1209-19. PubMed ID: 15298560
[TBL] [Abstract][Full Text] [Related]
13. T regulatory cells in allergen-specific immunotherapy.
Verhagen J; Taylor A; Blaser K; Akdis M; Akdis CA
Int Rev Immunol; 2005; 24(5-6):533-48. PubMed ID: 16318994
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of CXCR6 and CXCR3 in lymphocytes from birch-allergic patients.
Casas R; Lindau C; Zetterström O; Duchén K
Scand J Immunol; 2008 Sep; 68(3):351-61. PubMed ID: 18782262
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
[TBL] [Abstract][Full Text] [Related]
16. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
17. DNA-based approaches to the treatment of allergies.
Spiegelberg HL; Raz E
Curr Opin Mol Ther; 2002 Feb; 4(1):64-71. PubMed ID: 11883696
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of Th2 cytokine expression in atopic diseases.
van Panhuys N; Le Gros G; McConnell MJ
Tissue Antigens; 2008 Aug; 72(2):91-7. PubMed ID: 18554247
[TBL] [Abstract][Full Text] [Related]
19. An early imbalance of interleukin 12 influences the adjuvant effect of mannoproteins of Cryptococcus neoformans.
Pietrella D; Lupo P; Bistoni F; Vecchiarelli A
Cell Microbiol; 2004 Sep; 6(9):883-91. PubMed ID: 15272868
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of allergen specific immunotherapy--T-cell tolerance and more.
Jutel M; Akdis M; Blaser K; Akdis CA
Allergy; 2006 Jul; 61(7):796-807. PubMed ID: 16792576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
